Majid Adnan, Kheir Fayez, Fashjian Meghan, Chatterji Sumit, Fernandez-Bussy Sebastian, Ochoa Sebastian, Cheng George, Folch Erik
1 Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
2 Division of Pulmonary Diseases, Critical Care, and Environmental Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana.
Ann Am Thorac Soc. 2016 Feb;13(2):212-6. doi: 10.1513/AnnalsATS.201507-471BC.
There is a paucity of evidence regarding the role of tunneled pleural catheters in pleural effusions caused by congestive heart failure that is refractory to medical management.
The aim of this study was to assess the feasibility of tunneled pleural catheter drainage for treatment of refractory pleural effusions associated with congestive heart failure, either when used alone or with concomitant talc pleurodesis performed during thoracoscopy.
This was a retrospective cohort study. We identified patients with congestive heart failure and recurrent symptomatic pleural effusions who were treated between 2005 and 2015 by placement of a tunneled pleural catheter. Patients underwent either thoracoscopy followed by talc poudrage and pleural catheter placement (group 1) or catheter insertion alone (group 2).
Forthy-three catheters were inserted in 36 patients, with 15 placed in group 1 and 28 in group 2. Successful pleurodesis was seen in 80% in group 1 and 25% in group 2. The median time of catheter placement was 11.5 days in group 1 and 66 days in group 2. There was a significant decrease in hospital admissions and pleural interventions after catheter placement compared with before insertion (P < 0.05).
This single-center, retrospective study demonstrated the feasibility of catheter placement used alone or with talc poudrage for the treatment of refractory pleural effusions associated with congestive heart failure. The addition of talc poudrage might increase the pleurodesis rate and reduce the days to catheter removal in highly selected patients. Prospective studies on a larger number of patients are warranted to verify the safety and efficacy of this intervention.
关于隧道式胸腔导管在难治性充血性心力衰竭所致胸腔积液治疗中的作用,证据不足。
本研究旨在评估隧道式胸腔导管引流术单独使用或在胸腔镜检查期间联合滑石粉胸膜固定术治疗与充血性心力衰竭相关的难治性胸腔积液的可行性。
这是一项回顾性队列研究。我们确定了2005年至2015年间接受隧道式胸腔导管置入治疗的充血性心力衰竭和复发性症状性胸腔积液患者。患者接受了胸腔镜检查,随后进行滑石粉喷洒和胸腔导管置入(第1组)或仅进行导管插入(第2组)。
36例患者共插入43根导管,第1组15根,第2组28根。第1组80%的患者胸膜固定术成功,第2组为25%。第1组导管置入的中位时间为11.5天,第2组为66天。与导管插入前相比,导管置入后住院次数和胸腔干预次数显著减少(P < 0.05)。
这项单中心回顾性研究证明了单独使用导管或联合滑石粉喷洒治疗与充血性心力衰竭相关的难治性胸腔积液的可行性。在经过严格筛选的患者中,添加滑石粉喷洒可能会提高胸膜固定率并减少导管拔除天数。有必要对更多患者进行前瞻性研究,以验证这种干预措施的安全性和有效性。